ATTAIN-1 (NCT05869903), a 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron (6 mg, 12 mg, and 36 mg) as monotherapy vs
At the highest dose, up to 51.5 per cent of women in ATTAIN-1 achieved at least 15 per cent weight loss
Schedule a consultation today and lets find the path thats right for you.
TMates LLC presents itself as a U.S.-based telehealth platform headquartered in Miami, Florida that connects users with licensed medical providers through its online system
Ipsen filed a resubmission a few months later, which the FDA rejected in December 2022 and requested additional information regarding the data that the company had already provided
Consult with your healthcare provider before starting any new supplement regimen